Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03473223 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 18,226
- Enrollment target
NCT03473223: Completed Phase 3 study, sponsored by CSL Behring.
NCT03473223 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 18,226 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2264% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03473223, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 18,226 participants
- Enrollment target
Study Summary
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events \[MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke\] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.
Primary Outcome
MACE (Major adverse cardiovascular event\[s\])(CV \[cardiovascular\] death, MI \[Myocardial Infarction\], or stroke).
Interventions
- OTHER Placebo
- BIOLOGICAL Apolipoprotein A-I [human] (apoA-I)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,226 participants |
| Start Date | 2018-03-21 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 3 |
What the finished NCT03473223 record still lists
NCT03473223 is an interventional study that assigns participants to a tested intervention. Its 18,226 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2264% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03473223 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03473223 about?
NCT03473223 is a clinical study titled "Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome". This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events \[MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke\] in subjects with acute coronar...
What is the current status of trial NCT03473223?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 18,226 participants. The study started on 2018-03-21. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT03473223?
The interventions under investigation include: Placebo (OTHER), Apolipoprotein A-I [human] (apoA-I) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03473223?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03473223's enrollment target sits among peer trials
18,226 11th of 2000 higher than 1,990 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
- NCT05513833 · 18,000 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky
- NCT06802224 · 18,000 participants · Phase 4
The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
- NCT04372875 · 18,500 participants · NA
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI